Figure 1
Figure 1. Anti-ALK antibody titers according to the outcome of the ALCL patients. TRM indicates treatment-related mortality; and sec mal, secondary malignancy.

Anti-ALK antibody titers according to the outcome of the ALCL patients. TRM indicates treatment-related mortality; and sec mal, secondary malignancy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal